| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| MNKDMannKind Corporation | 1.73B | 5.64 | 58.02 | 43.5% | 9.32% | 1.89% | ||
| CORTCorcept Therapeutics Incorporated | 3.82B | 36.35 | 29.55 | 39.94% | 14.19% | 16.65% | 5.12% | 0.01 |
| GUTSFractyl Health, Inc. Common Stock | 308.28M | 2.01 | -1.24 | -22.5% | -40732.33% | -241.68% | 2.20 | |
| LXRXLexicon Pharmaceuticals, Inc. | 436.08M | 1.20 | -1.90 | 24.81% | -96.77% | -57.07% | 0.74 | |
| RZLTRezolute, Inc. | 229.96M | 2.48 | -2.53 | -52.45% | 0.01 | |||
| MISTMilestone Pharmaceuticals Inc. | 164.38M | 1.93 | -2.88 | -100% | -282.97% | 4.17 | ||
| ALTAltimmune, Inc. | 418.41M | 4.01 | -2.99 | -95.31% | -4195.75% | -45.21% | 0.01 | |
| BIOABioAge Labs, Inc. | 741.84M | 20.69 | -3.12 | -12.81% | -27.32% | 0.03 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 9.99M | 455K |
| Revenue Growth % | - | - | - | - | - | - | - | -0.95% |
| Cost of Goods Sold | 0 | 0 | 23K | 0 | 0 | 441K | 53.91M | 48.74M |
| COGS % of Revenue | - | - | - | - | - | - | 5.39% | 107.13% |
| Gross Profit | 0 | 0 | -23K | 0 | 0 | -441K | -43.91M | -48.29M |
| Gross Margin % | - | - | - | - | - | - | -4.39% | -106.13% |
| Gross Profit Growth % | - | - | - | 1% | - | - | -98.57% | -0.1% |
| Operating Expenses | 4.29M | 13.52M | 45.56M | 94.47M | 105.62M | 82.51M | 20.62M | 56.01M |
| OpEx % of Revenue | - | - | - | - | - | - | 2.06% | 123.1% |
| Selling, General & Admin | 582K | 2.05M | 13.21M | 32.68M | 43.05M | 27.32M | 20.62M | 56.01M |
| SG&A % of Revenue | - | - | - | - | - | - | 2.06% | 123.1% |
| Research & Development | 3.7M | 11.47M | 32.35M | 61.79M | 62.57M | 55.63M | 53.91M | 48.74M |
| R&D % of Revenue | - | - | - | - | - | - | 5.39% | 107.13% |
| Other Operating Expenses | 0 | 0 | 0 | 1 | 0 | -441K | -53.91M | -48.74M |
| Operating Income | -4.29M | -13.52M | -45.58M | -94.47M | -105.62M | -82.95M | -64.53M | -104.3M |
| Operating Margin % | - | - | - | - | - | - | -6.46% | -229.23% |
| Operating Income Growth % | - | -2.15% | -2.37% | -1.07% | -0.12% | 0.21% | 0.22% | -0.62% |
| EBITDA | 0 | 0 | -45.56M | -94.47M | -105.62M | -82.51M | -64.53M | -104.3M |
| EBITDA Margin % | - | - | - | - | - | - | -6.46% | -229.23% |
| EBITDA Growth % | - | - | - | -1.07% | -0.12% | 0.22% | 0.22% | -0.62% |
| D&A (Non-Cash Add-back) | 4.29M | 13.52M | 23K | 0 | 1.33K | 441K | 1K | 1K |
| EBIT | -4.28M | -14.88M | -45.51M | -94.47M | -105.62M | -82.51M | -64.53M | -104.3M |
| Net Interest Income | 0 | 0 | 0 | 0 | 0 | 685K | 1.37M | 3.53M |
| Interest Income | 0 | 0 | 93K | 559K | 555K | 685K | 1.37M | 3.53M |
| Interest Expense | 0 | 0 | 93K | 559K | 555K | 0 | 0 | 0 |
| Other Income/Expense | 3K | -3M | 69K | 505K | 34K | 442K | -55.23M | -1.32M |
| Pretax Income | -4.28M | -16.52M | -45.51M | -93.96M | -105.58M | -82.51M | -119.76M | -105.62M |
| Pretax Margin % | - | - | - | - | - | - | -11.98% | -232.14% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -4.28M | -16.52M | -45.51M | -93.96M | -105.58M | -82.51M | -119.76M | -105.62M |
| Net Margin % | - | - | - | - | - | - | -11.98% | -232.14% |
| Net Income Growth % | - | -2.86% | -1.75% | -1.06% | -0.12% | 0.22% | -0.45% | 0.12% |
| Net Income (Continuing) | -4.28M | -16.52M | -45.51M | -93.96M | -105.58M | -82.51M | -119.76M | -105.62M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.47 | -1.80 | -3.55 | -4.28 | -4.12 | -2.18 | -1.42 | -0.76 |
| EPS Growth % | - | -2.83% | -0.97% | -0.21% | 0.04% | 0.47% | 0.35% | 0.46% |
| EPS (Basic) | -0.47 | -1.80 | -3.55 | -4.28 | -4.12 | -2.18 | -1.42 | -0.76 |
| Diluted Shares Outstanding | 9.16M | 9.16M | 12.83M | 21.97M | 25.6M | 37.83M | 84.24M | 139.53M |
| Basic Shares Outstanding | 9.16M | 9.16M | 12.83M | 21.97M | 25.6M | 37.83M | 84.24M | 139.53M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 3.29M | 20.25M | 46.16M | 102.59M | 88.39M | 37.31M | 54.39M | 83.65M |
| Cash & Short-Term Investments | 3.28M | 18.75M | 38.85M | 96.83M | 80.82M | 30.58M | 49.9M | 79.4M |
| Cash Only | 3.28M | 18.75M | 18.85M | 57.47M | 53.89M | 16.66M | 49.9M | 79.4M |
| Short-Term Investments | 0 | 0 | 20M | 39.36M | 26.93M | 13.92M | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 505K | 0 | 275K | 285K | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | 10.41 | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 3.28M | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | 22.23 | - |
| Other Current Assets | 0 | 388K | 5.87M | 1.74M | 5.01M | 1.8M | -434K | 461K |
| Total Non-Current Assets | 0 | 0 | 2.23M | 1.91M | 1.5M | 1.05M | 447K | 3.04M |
| Property, Plant & Equipment | 0 | 0 | 2.04M | 1.91M | 1.3M | 1.05M | 447K | 2.79M |
| Fixed Asset Turnover | - | - | - | - | - | - | 22.36x | 0.16x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 199K | 0 | 200K | 0 | 0 | 253K |
| Total Assets | 3.29M | 20.25M | 48.39M | 104.51M | 89.89M | 38.36M | 54.83M | 86.69M |
| Asset Turnover | - | - | - | - | - | - | 0.18x | 0.01x |
| Asset Growth % | - | 5.16% | 1.39% | 1.16% | -0.14% | -0.57% | 0.43% | 0.58% |
| Total Current Liabilities | 993K | 4.43M | 14.1M | 21.23M | 26.46M | 33.42M | 71.18M | 27.3M |
| Accounts Payable | 713K | 3.02M | 8.79M | 640K | 9.46M | 4.53M | 1.74M | 4.43M |
| Days Payables Outstanding | - | - | 139.54K | - | - | 3.75K | 11.8 | 33.19 |
| Short-Term Debt | 0 | 0 | 0 | 1.07M | 789K | 622K | 310K | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 667K | 212K |
| Other Current Liabilities | 0 | 110K | 264K | 2.66M | 987K | 25.49M | 56.17M | 6.92M |
| Current Ratio | 3.31x | 4.57x | 3.27x | 4.83x | 3.34x | 1.12x | 0.76x | 3.06x |
| Quick Ratio | 3.31x | 4.57x | 3.27x | 4.83x | 3.34x | 1.12x | 0.72x | 3.06x |
| Cash Conversion Cycle | - | - | - | - | - | - | 20.84 | - |
| Total Non-Current Liabilities | 6.25M | 0 | 1.68M | 1.33M | 891K | 878K | 797K | 2.39M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 464K | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 1.68M | 1.33M | 891K | 414K | 38K | 2.39M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 6.25M | 0 | 0 | 0 | 0 | 0 | 759K | 0 |
| Total Liabilities | 7.25M | 4.43M | 15.78M | 22.57M | 27.35M | 34.3M | 71.98M | 29.68M |
| Total Debt | 0 | 0 | 2.04M | 2.81M | 2.12M | 1.98M | 777K | 2.79M |
| Net Debt | -3.28M | -18.75M | -16.81M | -54.65M | -51.77M | -14.68M | -49.12M | -76.6M |
| Debt / Equity | - | - | 0.06x | 0.03x | 0.03x | 0.49x | - | 0.05x |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | -490.13x | -168.99x | -190.30x | - | - | - |
| Total Equity | -3.96M | 15.82M | 32.61M | 81.94M | 62.54M | 4.06M | -17.15M | 57.01M |
| Equity Growth % | - | 4.99% | 1.06% | 1.51% | -0.24% | -0.94% | -5.22% | 4.32% |
| Book Value per Share | -0.43 | 1.73 | 2.54 | 3.73 | 2.44 | 0.11 | -0.20 | 0.41 |
| Total Shareholders' Equity | -3.96M | 15.82M | 32.61M | 81.94M | 62.54M | 4.06M | -17.15M | 57.01M |
| Common Stock | 0 | 0 | 1K | 2K | 3K | 5K | 8K | 35K |
| Retained Earnings | -4.74M | -21.26M | -66.77M | -160.73M | -266.31M | -348.82M | -468.59M | -574.21M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | -2K | -112K | -107K | 51K | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -3.19M | -11.18M | -36.31M | -78.21M | -90.73M | -78.09M | -55.17M | -84.31M |
| Operating CF Margin % | - | - | - | - | - | - | -5.52% | -185.29% |
| Operating CF Growth % | - | -2.5% | -2.25% | -1.15% | -0.16% | 0.14% | 0.29% | -0.53% |
| Net Income | -4.28M | -16.52M | -45.51M | -93.96M | -105.58M | -82.51M | -119.76M | -105.62M |
| Depreciation & Amortization | 0 | 0 | 23K | 380K | 415K | 443K | 354K | 425K |
| Stock-Based Compensation | 32K | 272K | 6.17M | 0 | 11.18M | 9.6M | 7.36M | 13.47M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 486K | 3M | -218K | 10.22M | -404K | 3.21M | 58.32M | 4.91M |
| Working Capital Changes | 569K | 2.06M | 3.23M | 5.15M | 3.67M | -8.84M | -1.44M | 2.52M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 499K | 2.3M | 5.75M | -8.04M | 8.82M | -4.93M | -2.79M | 2.69M |
| Cash from Investing | 0 | 0 | -20.01M | -19.47M | 12.43M | 13.17M | 13.87M | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 6.47M | 26.65M | 56.41M | 136.29M | 74.72M | 27.69M | 74.54M | 113.81M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - |
| Other Financing | 0 | -72K | -2.27M | 2.73M | 5.01M | 3.15M | 11.89M | 9.37M |
| Net Change in Cash | - | - | - | - | - | - | - | - |
| Free Cash Flow | -3.19M | -11.18M | -36.31M | -78.21M | -90.73M | -78.09M | -55.17M | -84.31M |
| FCF Margin % | - | - | - | - | - | - | -5.52% | -185.29% |
| FCF Growth % | - | -2.5% | -2.25% | -1.15% | -0.16% | 0.14% | 0.29% | -0.53% |
| FCF per Share | -0.35 | -1.22 | -2.83 | -3.56 | -3.54 | -2.06 | -0.65 | -0.60 |
| FCF Conversion (FCF/Net Income) | 0.75x | 0.68x | 0.80x | 0.83x | 0.86x | 0.95x | 0.46x | 0.80x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -278.67% | -187.97% | -164.06% | -146.16% | -247.77% | - | -529.97% |
| Return on Invested Capital (ROIC) | - | - | -531.42% | -328.91% | -416.28% | -80795.45% | - | - |
| Gross Margin | - | - | - | - | - | - | -439.43% | -10612.97% |
| Net Margin | - | - | - | - | - | - | -1198.47% | -23214.07% |
| Debt / Equity | - | - | 0.06x | 0.03x | 0.03x | 0.49x | - | 0.05x |
| Interest Coverage | - | - | -490.13x | -168.99x | -190.30x | - | - | - |
| FCF Conversion | 0.75x | 0.68x | 0.80x | 0.83x | 0.86x | 0.95x | 0.46x | 0.80x |
| Revenue Growth | - | - | - | - | - | - | - | -95.45% |
| 2023 | 2024 | |
|---|---|---|
| Research and Development Services | 774K | 455K |
| Research and Development Services Growth | - | -41.21% |
| License | 9.22M | - |
| License Growth | - | - |
Applied Therapeutics, Inc. (APLT) reported $1.0M in revenue for fiscal year 2024.
Applied Therapeutics, Inc. (APLT) saw revenue decline by 95.4% over the past year.
Applied Therapeutics, Inc. (APLT) reported a net loss of $18.1M for fiscal year 2024.
Applied Therapeutics, Inc. (APLT) has a return on equity (ROE) of -530.0%. Negative ROE indicates the company is unprofitable.
Applied Therapeutics, Inc. (APLT) had negative free cash flow of $86.8M in fiscal year 2024, likely due to heavy capital investments.